Posted by Teresa Graham on Feb 6th, 2026
Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to continued momentum in newer products and a late-stage pipeline that has expanded significantly over the past...
More of this article »